Discontinuation rates appear to highlight the speed and strength of weight loss was excessive for some patients with lower BMI, BMO wrote
Data from the EFFISAYIL program show spesolimab provides: Sustained reduction in flare frequency over 3 years ~75% of patients remaining flare-free Stable safety profile with no new signals Given the severity and unpredictability of GPP, these findings reinforce the value of targeted IL-36 inhibition for durable disease suppression
Bioavailability and inter-conversion of sulforaphane and erucin in human subjects consuming broccoli sprouts or broccoli supplement in a cross-over study design. Pharmacological research 64, no
Tataranni, T
3 Safety Considerations While semaglutide showed promise in managing chronic weight issues, common adverse effects associated with semaglutide encompass nausea, diarrhea, vomiting, constipation, abdominal pain, headaches, fatigue, indigestion, dizziness, abdominal bloating, belching, and hypoglycemia in patients with type 2 diabetes